» Articles » PMID: 11546936

CD4 T Cell Surface CCR5 Density As a Host Factor in HIV-1 Disease Progression

Overview
Journal AIDS
Date 2001 Sep 8
PMID 11546936
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Objective And Design: We have recently shown that the number of CCR5 molecules at the surface of peripheral blood CD4 T cells (CCR5 density) correlates with the viral RNA plasma level in HIV-1-infected individuals. As viral load is a strong predictor of outcome in HIV infection, the present study examines the correlation between CCR5 density and HIV-1 disease progression.

Methods: Using a quantitative flow cytometry assay, we measured CCR5 density in HIV-1-infected adults and control healthy volunteers. The CCR5 genotype (presence of a Delta 32 allele) was also determined.

Results: CCR5 density was stable over time on non-activated, HLA-DR(-)CD4 T cells of infected individuals. In a study cohort of 25 patients, asymptomatic and non-treated, we observed a correlation between CCR5 density on HLA-DR(-)CD4 T cells and the CD4 T cell slope (P = 0.026), which was independent of the presence or absence of the Delta 32CCR5 deletion. In particular, slow progressors expressed lower CCR5 densities than non-slow progressors (P = 0.004) and non-infected control subjects (P = 0.002).

Conclusion: These results are compatible with the hypothesis that CCR5 density, which is a key factor of HIV-1 infectability, determines in-vivo HIV production, and thereby the rate of CD4 cell decline. Consequently, CCR5 density quantitation could be a new valuable prognostic tool in HIV-1 infection. Moreover, these data emphasize the therapeutic potential of treatments that reduce functional CCR5 density.

Citing Articles

A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection.

Wahl A, Yao W, Liao B, Chateau M, Richardson C, Ling L Nat Biotechnol. 2023; 42(6):905-915.

PMID: 37563299 PMC: 11073568. DOI: 10.1038/s41587-023-01906-5.


Reduced CCR5 expression among Uganda HIV controllers.

Nyiro B, Amanya S, Bayiyana A, Wasswa F, Nabulime E, Kayongo A Retrovirology. 2023; 20(1):8.

PMID: 37231494 PMC: 10210444. DOI: 10.1186/s12977-023-00626-7.


CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.

Jasinska A, Pandrea I, Apetrei C Front Immunol. 2022; 13:835994.

PMID: 35154162 PMC: 8829453. DOI: 10.3389/fimmu.2022.835994.


Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers.

Picton A, Paximadis M, Koor G, Bharuthram A, Shalekoff S, Lassauniere R Front Immunol. 2022; 12:781263.

PMID: 34987508 PMC: 8720782. DOI: 10.3389/fimmu.2021.781263.


Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage.

Borrajo A, Ranazzi A, Pollicita M, Bellocchi M, Salpini R, Mauro M Medicina (Kaunas). 2019; 55(6).

PMID: 31234437 PMC: 6630780. DOI: 10.3390/medicina55060297.